# Jenburkt Pharma (NSE: JENBURPH) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/JENBURPH · Pivot · prices to 21 Oct 2026

Jenburkt Pharma (NSE: JENBURPH) closed at ₹914.80 on 21 Oct 2026, up 1.06% on the day. With a market capitalisation of ₹404 Cr, it ranks 1897th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

At its last close the stock traded at 11.6× trailing earnings, against a return on equity of 18.7% in FY25. Its 52-week range is ₹864.00 (8 Oct 2026) to ₹1,064.00 (31 Aug 2026); the last close is 14.0% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹36 Cr (−0.1% year on year) and net profit ₹6 Cr (−24.4%), on a standalone basis. Promoters held 46.62% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹914.80 |
| Market cap | ₹404 Cr |
| P/E (trailing) | 11.6 |
| ROE | 18.7% (FY25) |
| ROCE | 25.0% (FY25) |
| Debt to equity | 0.01 |
| 52-week high | ₹1,064.00 (31 Aug 2026) |
| 52-week low | ₹864.00 (8 Oct 2026) |

## Quarterly results (₹ crore, standalone)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q1 FY27 | ₹36 Cr | −0.1% | ₹6 Cr | −24.4% | ₹13.34 |
| Q4 FY26 | ₹45 Cr | +8.7% | ₹11 Cr | +27.0% | ₹24.58 |
| Q3 FY26 | ₹43 Cr | +16.6% | ₹6 Cr | −8.9% | ₹13.44 |
| Q2 FY26 | ₹46 Cr | +10.5% | ₹10 Cr | +5.8% | ₹23.03 |
| Q1 FY26 | ₹36 Cr | +9.2% | ₹8 Cr | +5.0% | ₹17.66 |
| Q4 FY25 | ₹41 Cr | +5.7% | ₹9 Cr | +8.4% | ₹19.34 |
| Q3 FY25 | ₹37 Cr | +3.4% | ₹7 Cr | +20.6% | ₹14.75 |
| Q2 FY25 | ₹41 Cr | +7.7% | ₹10 Cr | +31.1% | ₹21.75 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹152 Cr | ₹32 Cr |
| FY24 | ₹142 Cr | ₹26 Cr |
| FY23 | ₹137 Cr | ₹25 Cr |
| FY22 | ₹124 Cr | ₹22 Cr |
| FY21 | ₹109 Cr | ₹17 Cr |
| FY20 | ₹119 Cr | ₹15 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 46.62%
- Domestic institutions: 0.12%
- Non-institutions: 53.26%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Albert David](https://app.pivotnow.in/stock/ALBERTDAVD) | ₹788.95 | ₹450 Cr | — | — |
| [Asarfi Hospital](https://app.pivotnow.in/stock/ASARFI) | — | ₹446 Cr | — | — |
| [Transchem](https://app.pivotnow.in/stock/TRANSCHEM) | — | ₹391 Cr | — | — |
| [Aptus Pharma](https://app.pivotnow.in/stock/APPL) | — | ₹377 Cr | — | — |
| [Medicamen Biotech](https://app.pivotnow.in/stock/MEDICAMEQ) | ₹265.00 | ₹359 Cr | 36.7 | — |
| [Astal  Lab](https://app.pivotnow.in/stock/ASTALLTD) | — | ₹358 Cr | — | — |

## Questions and answers

### What is the share price of Jenburkt Pharma today?

Jenburkt Pharma (NSE: JENBURPH) last closed at ₹914.80 on 21 Oct 2026. Its 52-week high is ₹1,064.00 and its 52-week low is ₹864.00.

### What is the market cap of Jenburkt Pharma?

Jenburkt Pharma's market capitalisation is ₹404 Cr (₹404 Cr) at the 21 Oct 2026 close, ranking 1897th among the NSE companies Pivot tracks.

### What is the P/E ratio of Jenburkt Pharma?

Jenburkt Pharma trades at a trailing P/E of 11.6.

### What is the ROE and ROCE of Jenburkt Pharma?

Return on equity was 18.7% in FY25 and return on capital employed was 25.0% in FY25 (standalone figures).

### Is Jenburkt Pharma a debt-free company?

Jenburkt Pharma is close to debt-free: its debt-to-equity ratio was 0.01 in FY25.

### What were Jenburkt Pharma's latest quarterly results?

For Q1 FY27 (quarter ended 30 Jun 2026), Jenburkt Pharma reported revenue of ₹36 Cr, −0.1% year on year, and net profit of ₹6 Cr, −24.4% year on year.

### What is the shareholding pattern of Jenburkt Pharma?

As of 30 Jun 2026: promoters 46.62%, domestic institutions 0.12%, non-institutions 53.26%.

### Who are Jenburkt Pharma's competitors?

The listed Pharma & Healthcare companies closest to Jenburkt Pharma by market cap are Albert David, Asarfi Hospital, Transchem, Aptus Pharma, Medicamen Biotech and Astal  Lab.

### Is Jenburkt Pharma a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Jenburkt Pharma's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on JENBURPH against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.